<DOC>
	<DOCNO>NCT01362660</DOCNO>
	<brief_summary>This study examine post-natal neurologic cognitive development infant may expose tanezumab comparator in-utero tanezumab clinical program ( whether exposure maternal paternal participation tanezumab clinical study ) .</brief_summary>
	<brief_title>A Study Evaluate Infants With Potential Exposure Tanezumab Before Birth</brief_title>
	<detailed_description>This study enroll infant potential tanezumab exposure utero sit overseen Schulman Associates IRB This study attempt enroll infant qualify .</detailed_description>
	<criteria>Subject infant born mother expose study drug tanezumab clinical study direct maternal exposure ; infant born mother partner male patient expose study drug tanezumab clinical study prior around time conception and/or expose partner 's pregnancy . There exclusion criterion study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>post-natal monitoring</keyword>
	<keyword>exposure utero</keyword>
</DOC>